BARCELONA – Janssen Pharmaceuticals Inc. and Bayer AG will make an assault on the largely uncaptured market of coronary artery and peripheral arterial disease patients after the 27,000-patient COMPASS study showed that their Factor Xa inhibitor Xarelto (rivaroxaban) as an add-on to aspirin therapy reduced the risk of major adverse cardiovascular events compared to aspirin alone.
Full data for COMPASS (Cardiovascular Outcomes for People Using Anticoagulation Strategies) in coronary artery disease (CAD) and peripheral arterial disease...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?